Alpha Cognition Inc (ACOG) stock surged +0.24%, trading at $8.52 on NASDAQ, up from the previous close of $8.50. The stock opened at $8.50, fluctuating between $8.19 and $8.60 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 09, 2026 | 8.50 | 8.60 | 8.19 | 8.52 | 28.6K |
| Jul 08, 2026 | 8.10 | 8.50 | 8.08 | 8.50 | 107.47K |
| Jul 07, 2026 | 7.80 | 8.15 | 7.50 | 8.10 | 43.82K |
| Jul 06, 2026 | 8.17 | 8.21 | 7.65 | 7.90 | 46.02K |
| Jul 02, 2026 | 7.84 | 8.10 | 7.35 | 7.89 | 51.97K |
| Jul 01, 2026 | 7.19 | 7.99 | 6.90 | 7.79 | 33.17K |
| Jun 30, 2026 | 6.87 | 7.45 | 6.60 | 7.22 | 43.69K |
| Jun 29, 2026 | 6.56 | 6.90 | 6.56 | 6.81 | 18.58K |
| Jun 26, 2026 | 6.42 | 6.74 | 6.25 | 6.50 | 189.33K |
| Jun 25, 2026 | 6.59 | 6.65 | 6.37 | 6.50 | 51.63K |
| Jun 24, 2026 | 6.51 | 6.81 | 6.35 | 6.58 | 40.99K |
| Jun 23, 2026 | 6.72 | 6.75 | 6.45 | 6.58 | 61.09K |
| Jun 22, 2026 | 7.00 | 7.03 | 6.73 | 6.76 | 14.24K |
| Jun 18, 2026 | 6.72 | 7.03 | 6.12 | 6.91 | 25.62K |
| Jun 17, 2026 | 6.09 | 6.70 | 5.95 | 6.68 | 45.43K |
| Jun 16, 2026 | 6.05 | 6.09 | 5.85 | 6.01 | 24.96K |
| Jun 15, 2026 | 6.08 | 6.19 | 5.85 | 5.99 | 24.99K |
| Jun 12, 2026 | 6.00 | 6.31 | 5.91 | 5.99 | 46.8K |
| Jun 11, 2026 | 6.02 | 6.06 | 5.81 | 6.04 | 14.61K |
| Jun 10, 2026 | 6.05 | 6.15 | 5.89 | 5.99 | 36.22K |
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
| Employees | 71 |
| Beta | 2.37 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Financial Services |
| Industry | Financial - Conglomerates |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep